“
TL;DR
This study describes the preparation of a chitosan-based thermosensitive hydrogel designed for sustained release of murine nerve growth factor (mNGF) to treat neurotrophic keratopathy.
Neural Regeneration Research · 13 authors, 12 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This study describes the preparation of a chitosan-based thermosensitive hydrogel designed for sustained release of murine nerve growth factor (mNGF) to treat neurotrophic keratopathy.
The paper details the development of a chitosan-based thermosensitive hydrogel (CTH-mNGF) for sustained delivery of murine nerve growth factor (mNGF). The hydrogel is prepared by mixing chitosan and genipin solutions, then adding mNGF at 4°C to form a liquid that solidifies at physiological temperature. In vitro and murine corneal testing showed sustained mNGF release over 24 hours, with concentrations of approximately 1500 pg/mL in vitro and 1300 pg/mL in the cornea. The authors discuss that this formulation could reduce the dosing frequency required for effective neurotrophic keratopathy treatment compared to existing options like cenegermin. The study notes that while epithelial healing may occur early, corneal nerve regeneration is a slower, potentially indirect process.